Trial Profile

A multicenter, Phase 1 neoadjuvant study of ELI-002 7P in combination with mFOLFIRINOX with or without an anti-PD1 checkpoint inhibitor in borderline and resectable pancreatic ductal adenocarcinoma (PDAC)

Status: Planning

Phase of Trial: Phase I

Latest Information Update: 15 Dec 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

13 Nov 2025 According to Elicio Therapeutics media release, In August 2025, Elicio announced the positive recommendation by the Independent Data Monitoring Committee to continue the ELI-002 7P randomized Phase 2 study in PDAC without modifications to the final analysis.
06 Nov 2025 New trial record
29 Sep 2025 According to Elicio Therapeutics media release, The trial is expected to commence in first half of 2026.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com